Aktiia Funding News- Swiss HealthTech Startup Aktiia Raises €37M Funding

This latest funding round was very popular and had more investors than expected. It brings the company’s total funding to over €88 million.

The funding was led by Earlybird Health and Wellington Partners, with new investors Kfund and naturalX Health Ventures joining in. Existing investors like redalpine, Khosla Ventures, Molten Ventures, Translink Capital, and Verve Ventures also took part.

Raghav “Rags” Gupta, CEO of Hilo, commented: “This funding round is a testament to the confidence our investors have in Hilo’s groundbreaking technology and our mission to manage the world’s blood pressure via more frequent, convenient and accurate measurements. With billions worldwide suffering from hypertension, only 20% of whom are in control of their blood pressure, the need for innovative, accessible blood pressure monitoring solutions has never been greater. Our rebrand to Hilo represents more than just a name change, it’s a commitment to empowering users around the world with smarter tools to optimise their health. We are grateful to early Aktiia customers for their support and to our investors, new and existing, for their faith.”

Aktiia, now known as Hilo, was founded in 2018 to change the way blood pressure is tracked and managed. Instead of using traditional cuffs, Hilo uses advanced AI and data to create easy-to-use, cuffless blood pressure monitoring (CBPM) tools. These tools give clear, helpful reports for both users and healthcare professionals.

Hilo’s technology is based on a powerful AI model trained with billions of optical signals and hundreds of millions of blood pressure readings from over 120,000 people. The company’s expert team has published over 120 research papers and holds more than 35 patents.

This new Series B funding will help Hilo keep improving its products, grow into new markets, and develop its smart blood pressure platform for use by businesses and healthcare organizations.

Christoph Massner, Principal at Earlybird Health, who will join Hilo’s Board of Directors, commented: “Hilo stands at the intersection of medical-grade precision and consumer-centric accessibility. By building on a validated medical device platform and an intuitive, user-friendly design, they bridge the gap between clinical reliability and everyday usability. It’s a rare combination that empowers users to take meaningful control of their health with minimal effort. This is especially critical given the enormous medical need: uncontrolled high blood pressure remains one of the leading risk factors for death worldwide.”

Along with the new funding, Aktiia is changing its name to Hilo. This new brand reflects the company’s global goal: to make cuffless, medically approved blood pressure monitoring easy and available to everyone.

Johannes Fischer, Managing Partner at Wellington Partners, commented: “We are excited to co-lead this financing and to be backing Hilo’s innovative technology, which provides groundbreaking advancements to the billions of people with elevated blood pressure today. We believe that real-time and continuous access to blood pressure information will change the way we think about the monitoring and management of one of the most common risk factors to human health.”

About Aktiia

Aktiia is a Swiss company that makes a smart, cuff-free blood pressure monitoring device. The device looks like a bracelet and uses AI to track blood pressure continuously without needing a traditional cuff. It gives real-time information and helpful insights for both users and healthcare professionals.